Compounds > dpc 083
Page last updated: 2024-12-11

dpc 083

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5327770
CHEMBL ID29274
SCHEMBL ID1046528
SCHEMBL ID4088810
MeSH IDM0393249

Synonyms (23)

Synonym
bdbm2899
(4s)-6-chloro-4-[(e)-2-cyclopropylethenyl]-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinazolin-2-one
dpc083
bms-561390
(4s)-6-chloro-4-[(e)-2-cyclopropylvinyl]-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one
2(1h)-quinazolinone, 6-chloro-4-[(1e)-2-cyclopropylethenyl]-3,4-dihydro-4-(trifluoromethyl)-, (4s)-
ai-183
214287-99-7
dpc-083
CHEMBL29274
(4s)-6-chloro-4-[(e)-2-cyclopropylethenyl]-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one
unii-2498m8n65f
2(1h)-quinazolinone, 6-chloro-4-((1e)-2-cyclopropylethenyl)-3,4-dihydro-4-(trifluoromethyl)-, (4s)-
2498m8n65f ,
SCHEMBL1046528
SCHEMBL4088810
(4s)-6-chloro-4-((e)-2-cyclopropylvinyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1h)-one
(s)-6-chloro-4-(2-cyclopropylvinyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1h)-one
Q27253830
(s,e)-6-chloro-4-(2-cyclopropylvinyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1h)-one
uxdwyqaxegvsps-gfuiurdcsa-n
PD161046
AKOS040748010

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The best compounds are potent orally bioavailable inhibitors of both wild-type HIV-1 and its clinically relevant K103N mutant virus, but are highly protein-bound in human plasma."( 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
Bacheler, LT; Chidester, DR; Cocuzza, AJ; Cordova, BC; Diamond, S; Erickson-Viitanen, SK; Jeffrey, S; Klabe, RM; Ko, SS; Rodgers, JD; Weigelt, CA, 2001)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.02300.00060.91418.3200AID1795434
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.02300.00011.076810.0000AID1272056; AID197777
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC90 (µMol)0.04280.00170.03850.3100AID143399; AID198578; AID81765; AID81766
Protease Human immunodeficiency virus 1IC90 (µMol)0.70480.00200.67847.3000AID143396; AID143398; AID143402; AID94448; AID94450
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID94450Inhibitory concentration against wild-type virus K103N/L1001 and HIVdouble mutant in a whole cell antiviral assay2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID222922percentage of the free compound in human serum2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID96291Plasma Potency against Mutant HIV-1 sL100I2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID81765Compound was evaluated for its ability to inhibit a virus containing the clinically relevant K103N mutation2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID94312Calculated Potency against Mutant HIV-1 K103N2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID81766Compound was evaluated for its ability to inhibit the wild type RF strain of HIV-12001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID94448Inhibitory concentration against wild-type virus K103N mutant in a whole cell antiviral assay2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID222923percentage of the free compound in tissue culture medium2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID106727Antiviral activity against RF strain of HIV in MT-2 cells by RNA assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID152946Antiviral activity against Thai 9466, a wild-type clinical strain of HIV in PBMC by P24 assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID96289Calculated Potency against Mutant HIV-1 sL100I2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID106725Antiviral activity against E, Zidovudine resistant clinical strain of HIV in MT-2 cells by yield assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID106729Protein Binding was evaluated by PB shift in MT-2 by RNA assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID143402Compound was evaluated for its ability to inhibit the mutant K103N V1081NNRTI HIV-1 enzyme2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID141355Calculated Potency against Mutant HIV-1 sV179D/L100I/Y181C2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID141357Potency against Mutant HIV-1 sV179D/L100I/Y181C2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1272056Inhibition of HIV1 reverse transcriptase2016European journal of medicinal chemistry, Jan-27, Volume: 108Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
AID143398Compound was evaluated for its ability to inhibit the mutant K103N NNRTI HIV-1 enzyme2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID94442Potency against Mutant HIV-1 K103N2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID143399Compound was evaluated for its ability to inhibit the mutant K103N P225H NNRTI HIV-1 enzyme2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID106728Antiviral activity against RF strain of HIV in MT-2 cells by yield assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID152950Antiviral activity against A018C, Zidovudine resistant clinical strain of HIV in PBMC by P24 assay; ND is Not Determined.2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID94441Plasma Potency against Mutant HIV-1 K103N2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID197777Compound was evaluated for its ability to inhibit HIV-1 Reverse Transcriptase in an in vitro enzyme assay2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID106726Antiviral activity against HIV-2 in MT-2 cells by yield assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID143396Compound was evaluated for its ability to inhibit the mutant K103N L1001 NNRTI HIV-1 enzyme2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID251402Reduction of viral load after oral administration at 100 mg for 8 weeks; expressed as log10 reduction2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
New approaches toward anti-HIV chemotherapy.
AID166687Plasma antiviral activity was evaluated for RF strain of HIV-12000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID96292Potency against Mutant HIV-1 sL100I2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID141356Plasma Potency against Mutant HIV-1 sV179D/L100I/Y181C2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID198578Inhibitory concentration against HIV-1 reverse transcriptase2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID1795434HIV-1 RT Assay from Article 10.1016/s0960-894x(01)00239-6: \\4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.\\2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		210cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		210aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		4.2150acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
l-697661
L-697661: HIV-1 reverse transcriptase inhibitor		210
gw420867x
GW420867X: structure in first source		3.2310
uic-94003
UIC-94003: structure in first source		3.1210
dpc 961
[no description available]		4.2150
dpc 963
DPC 963: structure in first source		210
maraviroc
[no description available]		3.1210tropane alkaloid
vicriviroc
vicriviroc: structure in first source		3.1210(trifluoromethyl)benzenes
tak-220
TAK-220: structure in first source		3.1210
s 1360
[no description available]		3.1210
enfuvirtide
Enfuvirtide: A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.. enfuvirtide : A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.		3.1210
ConditionIndicatedRelationship StrengthStudiesTrials